Managing Patients with Psoriasis and Comorbidities: Cases, Evidence and Action Plans
Premiere Date: Friday, February 2, 2018This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, February 2, 2019
Note: Credit Is No Longer Available
 | Joel M. Gelfand, MD, MSCE Professor of Dermatology and Epidemiology Vice Chair of Clinical Research Medical Director, Dermatology Clinical Studies Unit Director, Psoriasis and Phototherapy Treatment Center University of Pennsylvania Perelman School of Medicine Philadelphia, PA |
 | Junko Takeshita, MD, PhD, MSCE Assistant Professor of Dermatology Assistant Professor of Epidemiology University of Pennsylvania Perelman School of Medicine Philadelphia, PA |
Psoriasis is a common chronic inflammatory skin condition that affects 3% to 4% of adults in the United States. Genetic susceptibility, immune dysregulation, and environmental factors are all thought to play a role in the development of the condition. Immunopathogenic studies have revealed that tumor necrosis factor alpha (TNF-α) and interleukins (IL-12, IL-17, IL-22, IL-23) are key cytokines involved in the pathogenesis of psoriasis. In recent years, there has been a focus on the development of treatment agents targeting these inflammatory cytokines. Despite the availability of effective treatments for psoriasis, physicians often fail to recognize psoriasis as a systemic inflammatory disease, resulting in significant undertreatment. Specifically, moderate and severe psoriasis are often treated with topical agents rather than more potent biologic and oral treatments, contributing to suboptimal outcomes and poor patient satisfaction.
In this CME Outfitters webcast, participants are presented with a real-world case scenario intermixed with nationally-known, expert faculty discussing the latest clinical data, guidelines, and quality measures and how they apply to the case as we add layers of complexity to our patient scenario. Finally, faculty discuss creating personalized clinical action plans for patients with psoriasis.
At the end of this CE activity, participants should be able to:
- Describe the pathophysiologic pathways underlying psoriasis and the rationale for treatment selection based on the MOA of agents that target these pathways.
- Identify the comorbidities common in patients with psoriasis and the impact of these comorbidities on treatment selection.
- Select appropriate treatments for patients with psoriasis based on disease characteristics, and efficacy and safety profiles of treatments.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe the pathophysiologic pathways underlying psoriasis and the rationale for treatment selection based on the MOA of agents that target these pathways.
- Identify the comorbidities common in patients with psoriasis and the impact of these comorbidities on treatment selection.
- Describe appropriate treatments for patients with psoriasis based on disease characteristics, and efficacy and safety profiles of treatment.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Dermatologists, Physician Assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriasis
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hours of pharmacotherapeutic contact hours.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.10 CEUs) Universal Activity Number:
Live: 0376-0000-18-002-L01-P
Enduring: 0376-0000-18-002-H01-P
Type: Knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST26337 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gelfand reports that he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc.; Celgene Corporation; Janssen Biologics, Inc. Novartis Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi. He is a consultant for Bristol-Myers Squibb Company; Coherus Biosciences; Dermira Inc.; Dr. Reddy?s Laboratories Ltd.; Janssen Biologics, Inc.; Menlo Therapeutics; Novartis Corporation; Pfizer Inc.; Sanofi; and Regeneron Pharmaceuticals, Inc. He receives other financial or material support as a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma.
Dr. Takeshita reports that she receives research grants from Pfizer Inc.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Daniela V. DiBiase, MS (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WCV-039-020218-45
